Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Comment by Winnipeg40on Oct 17, 2022 4:56pm
232 Views
Post# 35030033

RE:RE:RE:New Article

RE:RE:RE:New ArticleAggrastat's net realized price to MPH will likely decrease over the next 12-24 months by 50%-75%.  Contracts with US hospitals are typically for one year and that is for pricing. If an alternative is offered, they can just stop buying. There are no volume guarantees..period

Zypitimag was purchased for several million dollars although looking a their last few cash flow statements it does not appear that the scheduled payments are being made to the Company that sold it to them...they could lose this drug due to this anytime. 

Friesen has no issues buying shares...A CEO AND a PRES.  together making 500K a year....for what exactly?   Usually there is one person in this role, and even successful biotechs, the compensation is way less.  He is buying shares with shareholder money paid to him...for losing massive amounts of money for years.   Great gig if you can swing it. LOL  Again,   See my prior post...shareholders will get screwed IMO
<< Previous
Bullboard Posts
Next >>